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Abstract
Introduction: Vaccines may be key components of a curative strategy for HIV-1. We investigated whether a novel immuno-
gen, HIVconsv, designed to re-direct T cell responses to conserved viral epitopes, could impact the HIV-1 reservoir in chronic
antiretroviral therapy (ART)-treated subjects when delivered by modified vaccinia virus Ankara (MVA).
Methods: Nineteen virologically suppressed individuals were randomized to receive vaccinations with MVA.HIVconsv
(5.5 × 107 plaque-forming units, pfu, n = 8; 2.2 × 108 pfu, n = 7) or placebo (n = 4) at 0, 4 and 12 weeks. Magnitude,
breadth and antiviral function of vaccine-induced T cells, cell-associated HIV-1 DNA in circulating CD4+ T cells and residual
viremia in plasma were measured before and after vaccination.
Results: 90% of subjects completed the vaccine regimen; there were no serious vaccine-related adverse events. The
magnitude of HIVconsv-specific IFN-γ-secreting T cells was not significantly boosted in vaccinees when compared with
placebos in ex vivo Elispot assays, due to greater than expected variation in HIV-specific T cell responses in the latter during
the observation period. Ex vivo CD8+ T cell viral inhibitory capacity was modest but significantly increased post-vaccination
with MVA.HIVconsv at the higher dose (p = 0.004) and was positively correlated with the frequency of HIVconsv-specific CD8
+ CD107+ IFN-α± T cells (r = 0.57, p = 0.01). Total HIV-1 DNA and residual viral load did not change significantly from baseline
in any group.
Conclusions: Homologous prime-boost vaccination with MVA.HIVconsv was safe in HIV-positive ART-treated subjects but
showed modest immunogenicity and did not significantly change the size of the viral reservoir. MVA.HIVconsv may be more
effective when used in a heterologous prime-boost vaccination regimen and when combined with a latency-reversing agent.
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Introduction
Therapeutic immunization has attracted renewed interest
as a strategy to enhance immune-mediated clearance of
persistent HIV-infected CD4+ T cells during long-term anti-
retroviral therapy (ART), with the goal of purging the latent
viral reservoir to levels that are low enough to permit safe
interruption of ART [1]. Recently, vaccine candidates have
been tested either as the sole adjunct to ART or in
combination with ART and latency-reversing agents (LRAs)
as a means to “shock and kill” [2]. In the first scenario, it is
envisaged that vaccination would induce the expansion of
HIV-specific effector T cells with the capacity to kill virus-
producing CD4+ T cells, thus reducing the frequency of
latently infected cells and potentially delaying viral rebound
during ART interruption [3,4]. Immunization with a human
adenovirus vector expressing HIV Gag, a personalized
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vaccine based on autologous virus-pulsed dendritic cells or
a Gag p24-based peptide vaccine, have shown modest yet
statistically significant improvements in short-term virologi-
cal control off ART [5–7]. In the second scenario, it is
hypothesized that pharmacological reactivation of CD4+ T
cells is needed to induce viral protein production and thus
target the cell for immune recognition. This premise is
supported by in vitro models of HIV-1 latency reversal;
however, a poxvirus-vectored HIV-1 vaccine had only a
transient effect on viral rebound whether tested alone or
in combination with a candidate LRA, disulfiram in a phase I
clinical trial [8,9].
These studies have been pivotal in demonstrating the safety
and feasibility of testing new vaccines and LRAs and in assessing
short-term effects on viral reservoir parameters in ART-treated
subjects. However, more potent agents will be needed in order
to achieve therapeutic benefit.Most HIV immunogens tested to
date have been based on full-length HIV-1 proteins, an
approach that may lead to preferential expansion of T cell
clones targeting immunodominant and typically variable viral
epitopes that have already escaped, recapitulating the ineffec-
tive responses induced by natural infection [3,10]. In the HIV-
CORE 001 trial, we tested a conserved region immunogen,
HIVconsv, vectored by modified vaccinia virus Ankara (MVA)
in chronically infected ART-treated individuals. HIVconsv com-
prises 14 highly conserved regions of the viral proteome,
assembled end-to-end as a chimeric protein and balanced for
representation of the major clades, A-D. This vaccine had been
shown to be immunogenic in mouse and macaque models
prior to this trial [11,12].
By presenting the immune system with conserved HIV-1
sequences without the natural context of a full-length pro-
tein, we aimed to re-direct T cells towards viral epitopes
that are vulnerable and typically sub-dominant.
Methods
Study participants
We conducted a randomized double-blind placebo-controlled
study. This was approved by the Gene Therapy Advisory
Committee (GTAC 165), the Medicines and Health Products
Regulatory Agency (Eudract No. 2009-012662-31) and the
Oxford University Hospitals NHS Trust. Written informed con-
sent was obtained from all participants. Chronically HIV-
infected adults aged 18–60 years who were virologically sup-
pressed (<50 copies/ml) on combination ART and with CD4+
cell counts >350 cells/μl were randomly assigned in a 4:1 ratio
to receive vaccine or placebo in two groups of ten, the first
group receiving an MVA.HIVconsv dose of 5.5 × 107 plaque-
forming units (pfu) and the second, a dose of 2.2 × 108 pfu.
Subjects were HLA typed by amplification refractory mutation
sequencing (ARMS)-PCR using sequence-specific primers.
Randomization and masking
Study participants were randomly assigned to vaccine or
placebo according to the study protocol using a computer-
generated block randomization scheme, which was gener-
ated by an independent statistician and held securely with
restricted access.
Vaccine and vaccination schedule
The MVA.HIVconsv vaccine has been described previously
[11]. It was manufactured and diluted in formulation buffer
to 5 × 108 pfu/ml by IDT Biologika GmbH, Germany.
Formulation buffer was used as placebo. Vaccine and pla-
cebo vials were labelled by the manufacturer and stored at
−80°C until use. The vaccine was thawed ≤30 min prior to
administration and was given by intramuscular injection
with a needle and syringe into the deltoid region of both
arms (half of each dose per arm) on days 0, 28 and 84.
Safety evaluations included reactogenicity symptoms
recorded by the participants on diary cards following each
vaccination, physical examination and monitoring of labora-
tory parameters. Blood samples were taken for safety and
immunogenicity evaluations according to the study protocol
schema shown (Figure 1).
Peptides
HIVconsv peptides that span the HIVconsv immunogen (199
individual 15–17mer peptides overlapping by 11 amino
acids) were pooled in a matrix format. The use of a peptide
matrix enables deconvolution of the response and identifi-
cation of individual peptide-specific responses using a two-
step process [13]. First, fresh PBMCs from each time-point
Figure 1. Vaccination Schedule.
Volunteers were screened up to 28 days before vaccination and randomized on day 0 to receive either 5.5 × 107 pfu MVA.HIVconsv or
placebo (Arm A, subjects 1–10, 4:1 ratio) and either 2.2 × 108 pfu MVA.HIVconsv or placebo (Arm B, subjects 11–20, 4:1 ratio), by
intramuscular injection on days 0, 28 and 84. Blood was sampled on the days indicated.
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were tested against all matrix peptide pools in an IFN-γ
Elispot assay. Individual HIVconsv peptides from pools giv-
ing a positive response were then retested in a second IFN-
γ Elispot assay using cryopreserved PBMCs. Responses were
either confirmed as true positives or discounted. A 4-
dimensional matrix was designed using “Deconvolute This”
(version 1.0 Roederer) and comprised 80 pools with 10
peptides per pool. 96-well plates containing working pep-
tide pool stocks (4 µg/ml) were prepared in batches and
stored at −80°C until required; final peptide concentration
in the Elispot assay was 2 µg/ml.
Ex vivo IFN-γ elispot assay
IFN-γ Elispot assays were performed as described pre-
viously [14]. The total HIVconsv-specific response was
defined as the sum of the magnitude of all individual
HIVconsv peptides retested in the second-round assay
that elicited a response greater than the mean plus 2
standard deviations (SD) of negative control well values
(100 SFU/million PBMCs).
Intracellular cytokine assay
Intracellular cytokine secretion by antigen-specific T cell was
analyzed using multiparameter flow cytometry. Briefly, cryo-
preserved PBMCs were thawed, washed and rested over-
night in R10 medium at 37°C in a humidified incubator. Cells
were stimulated with HIVconsv peptide pools (2 µg/ml),
mock control and SEB (5 µg/ml) at 37°C for 6 h in the
presence of Golgiplug, Golgistop (BD Biosciences) and
CD107a BV421. Following viability and surface staining,
cells were then fixed using BD cytofix/cytoperm solution
(according to manufacturer’s instruction) and intracellularly
stained using reagents as listed in Supplementary Table 1. At
least 50,000 viable singlet CD3+ lymphocyte events were
acquired using BD Fortessa X20. Data were analyzed using
FlowJo v9.9.3 (FlowJo, US) and GraphPad Prism v7.0.
Viral inhibition assay
The viral inhibition assay has been described in detail pre-
viously [15]. CD8+ T cells were isolated from cryopreserved
PBMC by magnetic bead selection and used ex vivo without
stimulation. The CCR5-tropic clade B laboratory-adapted
HIV-1 isolate, BaL, was used for CD4+ T cell super-infection
at a multiplicity of infection of 0.01. CD8+ T cell antiviral
activity was reported as % inhibition.
Quantification of HIV-1 proviral DNA in CD4+ T cells
CD4+ cells were isolated from thawed PBMC by magnetic
bead selection. Lysed extracts from CD4+ T cells were used
to measure total cell-associated HIV-1 DNA by ddPCR with
primers and probes located in 5-LTR and Gag [16,17]. The
RPP30 cellular gene was quantified in parallel to normalize
sample input [18–20].
Residual plasma viremia
To evaluate HIV-1 RNA below 50 copies/ml, 3–5 ml of
plasma samples were ultracentrifuged and quantified
using the Abbott Real-Time HIV-1 assay (Abbott Molecular
Inc.), as previously described [21].
Statistical analysis
In view of the inter-subject variation in baseline responses
and response kinetics post-vaccination, HIVconsv-specific T
cell IFN-γ responses were analyzed over time and according
to group allocation using linear mixed effects models [22,23].
CD8+ T cell viral inhibitory activity and total HIV-1 DNA were
analyzed over time and according to group by non-para-
metric tests using Graphpad Prism software (version 7.0).
Censored matched pairs of ultrasensitive viral load were
analyzed using the paired Prentice-Wilcoxon test (MiniTab).
Results
Study participants and vaccinations
Nineteen subjects (14 men and 5 women) were enrolled in
the study. Enrolment was stopped prior to reaching the
planned 20 subjects due to slow recruitment. Vaccine and
placebo recipients did not differ significantly in age, CD4+
cell count, CD4+ cell nadir, duration of ART or duration of
diagnosed HIV infection at baseline. Volunteer characteris-
tics are summarized in Table 1. All volunteers received their
vaccinations as scheduled, except for one vaccinee in each
of the low- and high-dose groups, who both withdrew after
their second immunization (Figure 2).






n = 4 P Value
Male, n (%) 14 (70) 11 (73) 3 (75) -
Age, years 46 (43–46) 45 (42–48) 52 (47–52) 0.24
ART duration, months 37 (24–58) 41 (25–60) 26 (22–36) 0.35
CD4+ count, cells/µl 630 (470–830) 580 (445–960) 635 (608–650) 0.56
CD4+ pre-ART nadir, cells/µl 170 (250–330) 160 (90–229) 255 (210–288) 0.10
Known protective HLA class I alleles (n)* 5 5 0 -
ART duration and CD4+ count values are median (IQR).
*HLA-B*27, B51, B*5701/03, B*5801 and B*810.




Vaccination was safe and well tolerated. The majority (14/15)
of vaccine recipients experienced mild (n = 10) or moderate
(n = 4) pain at the injection site and 2/15 developed amild local
reaction. Nine vaccinees experienced mild to moderate
malaise, two reported mild headache and four reported “chills”
after vaccination. All of these reactions resolved spontaneously
within 48 h (Supplementary Table 2). Mild pain, headache and
moderate malaise were also reported by each of 3/4 placebo
recipients. No subject experienced a severe local or systemic
reaction. A total of 86 adverse events were reported during
following (66 in the vaccinees and 20 in the placebos); of these,
51 were grade 1, 27 were grade 2, five were grade 3; in three,
the grading scale was not applicable (Supplementary Table 3).
The grade 3 events occurring in vaccinees were all deemed to
be unrelated to vaccination (n = 3, vomiting requiring hospita-
lization followed by development of a pulmonary abscess;
pyelonephritis; gout). One placebo recipient developed
Hodgkin’s lymphoma. No unexpected or vaccine-related ser-
ious adverse events occurred during the trial.
All patients remained virologically suppressed (HIV RNA
<50 copies/ml) throughout follow up, apart from three subjects
who were found to have detectable viraemia (69–1404 copies/
ml) on a single occasion which was not confirmed on repeat
testing. CD4 cell counts did not change significantly during
follow up (p = 0.9, one-way ANOVA, Supplementary Figure 1)
T cell responses to MVA.HIVconsv
IFN-γ Elispot assays with the 4-dimensional HIVconsv peptide
matrix were performed using fresh PBMCs in all subjects at
screening, day 0, day 14, day 56 and day 266 time-points, as a
minimum. All deconvoluted matrix data up to day 56 were
collated and individual peptide sets for re-testing were
devised for each subject based on these data. The day 56
visit was chosen because the peak response was attained in
the majority of subjects after two MVA vaccinations in other
therapeutic vaccine trials [14,24]. The patient-specific peptide
sets were then tested using cryopreserved PBMC from each
time-point in a single IFN-γ Elispot assay. Pre-vaccination
responses to HIVconsv were detected in 16/19 subjects,
with amedian frequency of 798 (range 110–6807) SFU/million
PBMCs. Following vaccination, the peak response was not
synchronized among the vaccinees, in contrast to previous
studies of therapeutic vaccines encoding full-length HIV-1
proteins [14,25], and occurred between days 14 and 56. All
15 vaccinees had HIVconsv-specific responses above 100 SFU/
million PBMCs at the peak of response and the median fre-
quency was 1790 (range 180–10300) SFU/million PBMCs vs.
285 (range 110–6807) SFU/million PBMCs at baseline.
However, responses among placebos also showed variation
over time (Figure 3). In view of the inter-subject variation in
baseline responses and response kinetics post-vaccination,
linear mixed models were used to test for an interaction
between HIVconsv responses over time and vaccination. The
magnitude of responses increased significantly over time
(p = 0.001) but differences between vaccinees and placebos
were not statistically significant (p = 0.48) (Table 2A). IFN-γ
responses to an influenza/EBV/CMV peptide pool remained
constant during the study period, indicating that the variability
in HIVconsv responses was not due to technical issues such as
Figure 2. CONSORT flow diagram for recruitment and follow-up in the HIV-CORE 001 trial.
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variation in assay conditions (Supplementary Figure 2).
HIVconsv-specific responses in placebos were analyzed
further by multiparameter flow cytometry. This confirmed
the previously observed variation, not only in the frequency
of single IFN-γ-positive cells (Supplementary Figure 3) but also
in the frequency of polyfunctional T cells. Pre- and post-
vaccination responses to HIVconsv were distributed evenly
across the immunogen and increased in breadth over time
(Figure 4, Supplementary Table 4), although the difference
between vaccinees and placebos was statistically inseparable
(Table 2B). Responses were mediated predominantly by CD8+
T cells (Supplementary Figure 4). There was a significant
correlation between magnitudes of responses at baseline
and at the peak of response in the vaccinees (r = 0.63,
p < 0.0001; Supplementary Figure 5) suggesting that MVA.
HIVconsv vaccinations had boosted pre-existing responses.
CD8+ T cell antiviral activity was measured in all trial partici-
pants at one pre-and 2 post-vaccination time points, except for
one of the placebo recipients for whom sample limitations
permitted testing of two time-points only. The pre-vaccination
median inhibitory response was 24% overall (3.5%, 42% and
22% in placebos, low-dose and high-dose vaccinees respec-
tively) when measured at a CD4+/CD8+ T cell ratio of 1:1
(p = 0.057, Kruskal–Wallis test). At the peak of response post-
vaccination, median inhibition was 4.6%, 12.5% and 54% in
placebos, low-dose and high-dose vaccinees respectively. In
the high-dose vaccinees there was a statistically significant
increase in inhibition following vaccination with MVA.
HIVconsv (p = 0.004, Friedman test; Figure 5), but no such
trend was observed in the placebos or low-dose vaccinees
(p = 0.19 and 0.29, respectively). Analysis was limited due to
sample issues resulting in only 3 data points in the placebo
group at peak. For this reason, we performed a 1‐way ANOVA
to increase statistical power when comparing inhibition long-
itudinally in vaccinees and placebos. A 1‐way ANOVA of viral
inhibition in high-dose and low-dose vaccine groups combined
did not show any significant increases post vaccination.
The phenotype of HIVconsv-specific CD4+ and CD8+ T cell
responses was assessed by intracellular cytokine staining in
all volunteers at time points corresponding to their peak
Elispot responses. No significant differences in magnitude
or phenotype were found between CD8+ T cell responses in
placebos, low- or high-dose vaccinees. There was, however,
Figure 3. T cell immunogenicity of MVA.HIVconsv in volunteers over time.
Total magnitude of T cell responses to the HIVconsv immunogen was assessed in ex vivo IFN-γ ELISPOT assays in (L to R) placebos, low dose
vaccinees and high dose vaccinees shown as (a) box and whisker plot (median, IQR and range) and (b) line graphs (representing each
subject). Total magnitude was calculated from the sum of all HIVconsv individual peptides tested in a confirmatory second round assay which
gave a response above the mean plus 2* SD of negative control wells (100 SFU/million PBMCs, see Materials and Methods). BL – baseline.
Table 2. Linear mixed model investigating the effect of
MVA.HIVconsv vaccination on (A) magnitude and (B) breadth
of responses over time
Variable dF F p
A
Intercept 644 17.2 0.00004
Time (days)* 644 3.3 0.00100
Group§ 17 0.5 0.48300
B
Intercept 70 28.1 0.000001
Time (days)* 70 2.90 0.007900
Group§ 16 0.59 0.450000
Linear mixed-effects models were fitted to the data following a
described model formulation [22] and computational framework
[23] to investigate the effect of MVA.HIVconsv vaccination on the
(A) magnitude of response and (B) breadth of response over time
(Variable; time*) and between vaccines and placebos (Variable;
group§). Breadth was defined as the number of positive peptides
(response over 100 SFU/106 PBMC) at each time point.
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a significantly higher frequency of polyfunctional CD4+ T
cells in the high dose vaccines (Figure 6(a)). Interestingly,
per cent inhibition was positively correlated with the fre-
quency of HIVconsv-specific CD8+ CD107+ IFN-γ+ TNF-α +/-
T cells (r = 0.57, p = 0.01) but not with the frequency of CD8
+ CD107- IFN-γ+ TNF-α +/- T cells (r = 0.01 p = 0.94)
(Figure 6(b,c).
Effect of MVA.HIVconsv vaccinations on the HIV-1
reservoir
Using the upper end of the reported cutoff for detection of
HIV-1 DNA by ddPCR (2 copies/106 cells), HIV-1 DNA was
detected in all study subjects at all time-points tested
(medians 1065, 1014 and 1182 copies/106 CD4+ T cells at
weeks 0, 6 and 38 respectively; Figure 7(a)). Copies of HIV-1
Figure 4. Breadth of pre- and post-vaccination responses to HIVconsv.
Location of confirmed positive peptides across the HIVconsv immunogen pre and post-vaccination (included if peptide was above 100 SFU/
million PBMCs at any time-point after screening/day 0). Left-hand column shows peptide numbers according to antigenic origin: pink – gag;
blue – pol; purple – vif; turquoise – env; grey – junctional peptide (15-mer peptides that span junctions between segments from different
proteins or between segments from the same proteins yet from different clades). Colour and number in boxes indicate magnitude of
response. Patient numbers outlined with a black box indicate placebo volunteers.
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DNA/106 CD4+ T cells at baseline did not correlate with CD4
+ T cell nadir (r = 0.42, p = 0.15), CD4+ cell count (r = −0.23,
p = 0.33), interval between diagnosis and initiation of
treatment (r = 0.17, p = 0.54) or duration of ART. There
was no change from baseline in the size of the reservoir at
week 6 or week 38 post-vaccination in the vaccinees as a
whole (medians 1032, 944 and 960 copies HIV-1 DNA/106
CD4+ T cells, p = 0.77; Friedman test) or placebos (medians
1652, 2058 and 1351 copies HIV-1 DNA/106 CD4+ T cells,
p = 0.65; Friedman test; Figure 7(a)). Stratification of vacci-
nees into low- and high-dose groups also did not reveal any
significant changes post-vaccination (weeks 0, 6 and 38
Figure 6. Induction of polyfunctional HIVconsv-specific CD4+ and CD8+ T cell responses.
(a) Box and whisker plot showing background-subtracted CD154/IFN-γ/TNF-α/IL2-positive CD4+ T cell responses to HIVconsv pools stratified
by dose (* = p < 0.05, Mann Whitney test). Relationship between CD8+ T cell antiviral activity (% inhibition) and frequencies of CD8+ T cells
with either (b) CD107+IFN-γ+TNF-α+/- or (c) CD107-IFNγ+TNFα+/- phenotypes. Pearson R correlation analysis.
Figure 5. CD8+ T antiviral activity is increased following vaccination with a higher dose of MVA.HIVconsv.
CD8+ T cell-mediated inhibition of HIV-1Bal in autologous CD4+ T cells (CD8+/CD4+ cell ratio = 1:1) was measured in all 19 trial participants at
baseline (Screening or day 0), post-vaccination, concurrent with the peak response in the IFN-γ Elispot assay, and at a late post-vaccination time-
point (day 182 or day 266) except one placebo recipient (pre-vaccination and peak only). This individual was therefore excluded from the statistical
analysis. Grey line indicates median response. Asterisks indicate statistically significant differences in multiple comparisons analysis.
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medians for low-dose 1074, 1260 and 1272 copies HIV-1
DNA/106 CD4+ T cells, p = 0.65; and high-dose 827, 721 and
577 copies HIV-1 DNA/106 CD4+ T cells, p = 0.23; Friedman
test). When HIV-1 DNA was expressed as a ratio of week 6
or week 8 to baseline values, this confirmed that there was
no significant change during the study (Figure 7(b)). We
detected residual plasma viremia in 47% of the patients,
with a range limit of detection (LOD) of 0.6–0.9 copies HIV-
1 RNA/ml of plasma (Figure 7(c)). We observed no changes
from baseline in the ultrasensitive viral load at weeks 6 or
38 post-vaccination in any group (low-dose, p = 0.68 and
0.12 respectively; high-dose, p = 0.32 and 0.32 respectively;
placebo, p = 0.32 and 0.53, respectively; paired Prentice-
Wilcoxon test; Figure 7(d)).
Discussion
We investigated the immunogenicity of a conserved region
immunogen, HIVconsv, for the first time in HIV-1 infected
individuals on ART. A homologous prime-boost regimen of
three MVA.HIVconsv vaccinations was safe and well toler-
ated. Interferon-γ T cell responses to conserved epitopes,
many of which are subdominant in natural infection, were
increased after vaccination. However, the magnitude of the
change was not significantly greater in vaccinees than pla-
cebos, due to an unanticipated level of variation in
responses over time in the latter. By contrast, responses
to non-HIV-1 antigens remained constant during the study
period in vaccinees and placebos. This highlights the natural
intra-individual variation in HIV-specific T cell responses in
long-term ART-treated patients, which has not been exten-
sively reported before [26]. Furthermore, mapping enabled
us to detect a large number of responses to viral epitopes
that are infrequently recognized in natural infection, as
they were restricted by HLA alleles other than that had
been defined previously. This indicates that the HIVconsv
immunogen was re‐directing responses to subdominant
epitopes but as we did not map T cell responses to the
entire HIV proteome we cannot prove this point.
These could be attractive targets for more potent immu-
notherapeutic approaches to purge reactivated CD4+ T cells
in which “CTL-resistant” viruses predominate [27]. More
potent T cell responses might be elicited using heterologous
vaccination regimens comprising a replication-defective
chimpanzee adenovirus vector prime followed by MVA
boost, as we have reported previously in a trial in healthy
HIV-uninfected individuals [28]. Preliminary data indicate
that this approach is similarly immunogenic in HIV-positive
patients initiating ART during primary infection [29].
In contrast to the lack of effect on IFN-γ responses,
vaccination with MVA.HIVconsv did appear to enhance
the antiviral inhibitory capacity of CD8+ T cells as there
Figure 7. Quantification of the HIV reservoir following vaccination with MVA.HIVconsv.
(a) Total HIV-1 DNA (copies/million CD4+ T cells) was measured by quantitative ddPCR in trial participants at baseline (BL), week 6* and
week 38. (b) Fold change of total HIV-1 DNA to baseline. (c) Ultrasensitive viral load (HIV-1 RNA/ml plasma) was measured by Abbott Real-
Time HIV-1 assay at baseline, week 6 and week 38. (d) Fold change of ultrasensitive viral load to baseline. *In three volunteers total HIV-1
DNA was measured at week 9 or week 12 rather than week 6 due to sample availability, and there was no plasma sample at week 6 for one
patient of the placebo group. Dark lines indicate median values for each group and light lines indicate individual values.
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was a significant increase in the subjects receiving the
higher dose (2.2 × 108 pfu). Although there was also varia-
tion in the placebos, this was not statistically significant.
The level of antiviral activity was strongly correlated with
the frequency of polyfunctional CD8+ T cells with lytic
potential, indicated by upregulation of CD107. The inhibi-
tory activity was still below levels that we have observed in
individuals who spontaneously control HIV-1, therefore,
these results need to be interpreted with caution [15,30].
The modest responses in the patients studied here may
reflect irreversibly compromised CD4+ T cell helper func-
tion: although we could detect a significantly higher fre-
quency of polyfunctional CD4+ T cells in the high dose
vaccinees, which indicates a degree of T helper function,
such responses might be better preserved if ART had been
started earlier. This issue has since been addressed in
another clinical trial [29].
We reasoned that therapeutic vaccination with MVA.
HIVconsv could reduce the size of reservoir through reacti-
vation of latently infected cells [31], for example, via the
TLR1/2 signalling pathway [32,33]. In addition, re-expansion
of HIV-1-specific CD8+ T cell populations could accelerate
the clearance of CD4+ T cells that express cognate epitopes
at sufficient levels for immune recognition, whether reacti-
vated or resting [34]. In this study, HIV-1 reservoir size and
residual plasma viremia, as measured by total HIV-1 DNA
copies in CD4+ T cells and ultrasensitive viral load respec-
tively, did not change significantly after vaccination. While it
is possible that viral blips may have occurred in the inter-
vals between vaccination and blood samples, the data
suggest that recombinant MVA vaccination alone does not
reactivate latent HIV-1 nor induce T cell responses of suffi-
cient potency to perturb the reservoir. This is consistent
with another study investigating the effects of an MVA-
vectored vaccine encoding HIV-1 Gag [8]. A similar
approach involving a DNA /recombinant human adenovirus
type 5 prime-boost HIV-1 vaccination strategy in chronically
infected patients receiving intensified ART also failed to
increase HIV-1 expression or reduce the size of the reser-
voir [35]. These findings indicate that HIV latency reversal
must be synergized with killing by vaccine-induced T cells. T
cells must also be able to recognize the epitopes generated
by reactivated cells during a short window and ideally
target regions of vulnerability that are known to lead to
loss of viral fitness upon CD8+ T cell attack in vivo [36].
Some of these regions were not included in the HIVconsv
immunogen because they were not highly conserved;
refinement of the immunogen design may be necessary to
ensure boosting of the most potent CD8+ T cell responses
[30,37–40]. Analysis of the HLA class I-associated pepti-
dome could facilitate this as we have recently shown,
using tandem mass spectrometry, that the HLA class
I-associated HIV-1 peptidome on primary CD4+ T cells
includes a substantial proportion of epitopes that had not
been described previously [41].
This study is, to our knowledge, the first to investigate the
relationship between the HIV-1 reservoir size and CD8+ T cell
viral inhibitory activity in chronic ART-treated patients. These
parameters were not correlated before or after vaccination,
possibly reflecting the stability of the reservoir after a med-
ian 6 years of infection, and the limited capacity of the
vaccine to enhance CD8+ T cell viral inhibitory activity.
Our study has some limitations. It was underpowered to
discern differences in the magnitude of T cell responses
between vaccine and placebo recipients. The extent of
natural variation in HIV-specific T cell responses during
ART needs to be considered in the design of future studies.
Despite randomization, the vaccinees and placebos were
not balanced for protective HLA class I alleles, although this
does not appear to have influenced the immunogenicity
results. Finally, we used a single assay to quantify the HIV-1
reservoir, based on total, rather than integrated HIV-1. We
reasoned that unintegrated forms of HIV-1 DNA make only
a small contribution to the size of the viral reservoir after
1 year of ART [42]. Furthermore, total HIV-1 DNA was
predictive of time to viral rebound during a supervised
therapy interruption in patients treated with ART during
primary infection [43].
Conclusions
Our study highlights the need for further optimization of
therapeutic vaccines for inclusion in HIV-1 eradication stra-
tegies. In addition, the high degree of variability in HIV-
specific IFN-γ T cell responses during long-term ART needs
to be considered in clinical trial design; testing of candidate
immunological endpoints that are predictive of changes in
the viral reservoir is a critical component of such studies.
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